| 0 (0%) | 01-19 18:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.96 |
1-year : | 21.88 |
| Resists | First : | 17.09 |
Second : | 18.73 |
| Pivot price | 15.6 |
|||
| Supports | First : | 14.44 |
Second : | 12.01 |
| MAs | MA(5) : | 15.22 |
MA(20) : | 15.58 |
| MA(100) : | 13.63  |
MA(250) : | 12.73 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 10.9 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 18.73 | Low : | 8.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KALV ] has closed above bottom band by 7.8%. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.17 - 15.26 | 15.26 - 15.35 |
| Low: | 14.21 - 14.3 | 14.3 - 14.4 |
| Close: | 14.42 - 14.59 | 14.59 - 14.76 |
Fri, 16 Jan 2026
A Quick Look at Today's Ratings for KalVista Pharmaceuticals(KALV.US), With a Forecast Between $29 to $39 - 富途牛牛
Thu, 15 Jan 2026
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - Yahoo Finance
Sat, 10 Jan 2026
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Fri, 09 Jan 2026
$KALV stock is up 18% today. Here's what we see in our data. - Quiver Quantitative
Fri, 09 Jan 2026
KALV: Needham Raises Price Target to $35, Maintains Buy Rating | - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 51 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 123.7 (%) |
| Shares Short | 15,390 (K) |
| Shares Short P.Month | 14,450 (K) |
| EPS | -3.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | -336.4 % |
| Return on Assets (ttm) | -61 % |
| Return on Equity (ttm) | -190.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.18 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -167 (M) |
| Levered Free Cash Flow | -100 (M) |
| PE Ratio | -3.71 |
| PEG Ratio | 0 |
| Price to Book value | 42.94 |
| Price to Sales | 516.1 |
| Price to Cash Flow | -4.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|